Jane de Lartigue, PhD | Authors


Novel Approaches Tackle the JAK Pathway Beyond Ruxolitinib and Myelofibrosis

March 21, 2018

Since the identification of the role of the JAK kinase family in the late 1980s, awareness of this has grown significantly. These tyrosine kinases have been proven to transmit a variety of signals into the cells with many biological consequences, adding to the interest in the targetability of the JAK pathway. However, better understanding of the complexities of JAK signaling are being evaluated in clinical trials.

CAR T-Cell Therapy Hits Prime Time; Challenges Remain

November 13, 2017

Chimeric antigen receptor T cells have hit the prime time, with 2 FDA approvals already for this class of cellbased therapy. Undoubtedly this will be a game changer for patients with B-cell malignancies who have a small number of treatment options; however, questions regarding the realworld application of CAR T-cell therapies remain.

Update on Next-Generation Therapies for NSCLC

July 31, 2014

Treatment for non-small cell lung cancer (NSCLC)—which includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma—has traditionally consisted of surgery, chemotherapy, and radiation therapy.